Minerva Neurosciences Announces Board and Executive Changes

Ticker: NERV · Form: 8-K · Filed: May 30, 2024 · CIK: 1598646

Sentiment: neutral

Topics: executive-compensation, board-changes, personnel

Related Tickers: NRNE

TL;DR

Minerva Neurosciences shakes up board, sets CEO salary at $450k.

AI Summary

Minerva Neurosciences, Inc. announced on May 29, 2024, changes in its board of directors and executive compensation. Dr. Jonathan F. Miller has been appointed as a new director, and the company has entered into new employment agreements with certain officers, including an annual base salary of $450,000 for its Chief Executive Officer, Dr. Alted, effective May 29, 2024.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or leadership focus, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in leadership and executive compensation can introduce uncertainty regarding future strategic direction and operational stability.

Key Numbers

Key Players & Entities

FAQ

Who has been appointed as a new director to the board of Minerva Neurosciences?

Dr. Jonathan F. Miller has been appointed as a new director.

What is the new annual base salary for the CEO of Minerva Neurosciences?

The new annual base salary for the CEO, Dr. Alted, is $450,000.

When were these changes effective?

The changes were effective as of May 29, 2024.

What specific items are being reported in this 8-K filing?

This 8-K reports the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.

What is the principal executive office address for Minerva Neurosciences?

The principal executive offices are located at 1500 District Avenue, Burlington, MA 01803.

Filing Stats: 502 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2024-05-30 16:25:30

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MINERVA NEUROSCIENCES, INC. Dated: May 30, 2024 By: /s/ Geoffrey Race Name: Geoffrey Race Title: President

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing